A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro

Immunology Letters

Volumn 154, Issue 1-2, 2013, Pages 18-24

  Zhu, Xiaoying ^a   Tao, Kun ^a   Li, Yajuan ^a   Li, Shenfeng ^a   Zhang, Lijun ^a   Wang, Dong ^a   Zhong, Liang ^a   Feng, Wenli ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myeloid leukemia; HscFv; Recombinant immunotoxin; Targeting therapy

Indexed keywords

HUMANIZED SINGLE CHAIN FRAGMENT VARIABLE EXOTOXIN A; IMMUNOTOXIN; ISOPROPYL THIOGALACTOSIDE; NICKEL; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL STRAIN K 562; CELL STRAIN KU812; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOPLASM; DELETION MUTANT; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION;

CHRONIC MYELOID LEUKEMIA; HSCFV; RECOMBINANT IMMUNOTOXIN; TARGETING THERAPY;

ADP RIBOSE TRANSFERASES; APOPTOSIS; BACTERIAL TOXINS; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; EXOTOXINS; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; VIRULENCE FACTORS;

EID: 84883706233     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.08.002     Document Type: Article

References (38)

1. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
2. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
3. Hartmann J.T., Haap M., Kopp H.G., Lipp H.P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009, 10:470-481.
4. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001, 1:118-129.
5. Safavy A., Bonner J.A., Waksal H.W., Buchsbaum D.J., Gillespie G.Y., Khazaeli M.B., et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 2003, 14:302-310.
6. Carter P.J., Senter P.D. Antibody-drug conjugates for cancer therapy. Cancer J 2008, 14:154-169.
7. Stan A.C., Radu D.L., Casares S., Bona C.A., Brumeanu T.D. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res 1999, 59:115-121.
8. Wels W., Harwerth I.M., Mueller M., Groner B., Hynes N.E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 1992, 52:6310-6317.
9. Gustin A., Pederson L., Miller R., Chan C., Vickers S.M. Application of molecular biology studies to gene therapy treatment strategies. World J Surg 2002, 26:854-860.
10. Bernstein I.D. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000, 14:474-475.
11. Ghetie V., Vitetta E.S. Chemical construction of immunotoxins. Mol Biotechnol 2001, 18:251-268.
12. Kreitman R.J. Immunotoxins. Expert Opin Pharmacother 2000, 1:1117-1129.
13. Kreitman R.J., Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 1995, 307(Pt 1):29-37.
14. Kreitman R.J., Puri R.K., Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res 1995, 55:3357-3363.
15. Engebraaten O., Sivam G., Juell S., Fodstad O. Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int J Cancer 2000, 88:970-976.
16. Kreitman R.J., Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymphoma 1994, 13:1-10.
17. Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A 1991, 88:8616-8620.
18. Schmidt M., Wels W. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha. Br J Cancer 1996, 74:853-862.
19. Lory S., Strom M.S., Johnson K. Expression and secretion of the cloned Pseudomonas aeruginosa exotoxin A by Escherichia coli. J Bacteriol 1988, 170:714-719.
20. Kreitman R.J. Chimeric fusion proteins-Pseudomonas exotoxin-based. Curr Opin Investig Drugs 2001, 2:1282-1293.
21. Liu D., Wang C., Li C., Zhang X., Zhang B., Mi Z., et al. Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein. J Biol Chem 2011, 286:24500-24507.
22. Chowdhury P.S., Viner J.L., Beers R., Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998, 95:669-674.
23. Wang D., Zhang L., Li Y., Wang H., Xiao Q., Cao W., et al. Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells. Biotechnol Lett 2012, 34:1193-1201.
24. Zhu X., Wang D., Li S., Xiao Q., Tao K., Hu J., et al. Expression of a humanized single-chain variable fragment antibody targeting chronic myeloid leukemia cells in Escherichia coli and its characterization. Int J Mol Med 2012, 29:939-945.
25. Tur M.K., Rothe A., Huhn M., Goerres U., Klimka A., Stocker M., et al. A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. Int J Mol Med 2003, 11:523-527.
26. Wang T., Zhao J., Ren J.L., Zhang L., Wen W.H., Zhang R., et al. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res 2007, 67:11830-11839.
27. Huhn M., Sasse S., Tur M.K., Matthey B., Schinkothe T., Rybak S.M., et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001, 61:8737-8742.
28. Trail P.A., King H.D., Dubowchik G.M. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003, 52:328-337.
29. Barth S., Huhn M., Wels W., Diehl V., Engert A. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int J Mol Med 1998, 1:249-256.
30. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001, 345:241-247.
31. Bruell D., Stocker M., Huhn M., Redding N., Kupper M., Schumacher P., et al. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 2003, 23:1179-1186.
32. Pai L.H., Wittes R., Setser A., Willingham M.C., Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996, 2:350-353.
33. Grossbard M.L., Gribben J.G., Freedman A.S., Lambert J.M., Kinsella J., Rabinowe S.N., et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993, 81:2263-2271.
34. Baluna R., Rizo J., Gordon B.E., Ghetie V., Vitetta E.S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 1999, 96:3957-3962.
35. Kreitman R.J., Wilson W.H., Robbins D., Margulies I., Stetler-Stevenson M., Waldmann T.A., et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999, 94:3340-3348.
36. Kawakami K., Kawakami M., Puri R.K. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 2001, 21:299-310.
37. Mathew M., Verma R.S. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009, 100:1359-1365.
38. Kreitman R.J. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009, 23:1-13.